CERTAINTY WITHIN 15 MINUTES Artikel in deutscher Sprache anzeigen
AESKU.RAPID SARS-CoV-2 Antigen Rapid Test
The CE certified AESKU.RAPID SARS-CoV-2 Rapid Test is based on immunochromatographic polymer technology combined with the sandwich principle for the qualitative detection of the nucleocapsid protein antigen in human nasal swab specimens. The specimen is placed in the test device's specimen well with colored polymer-labeled monoclonal SARS-CoV-2 antibody 1 and mixed along the nitrocellulose membrane chromatographed.
If SARS-CoV-2 antigens are present in the sample, they bind to the SARS-CoV-2 antibody 1.The mixture then binds to the immobilized SARS-CoV-2 antibody 2 on the nitrocellulose membrane. The resulting complex of antibody 1, antigen, and antibody 2 forms the colored test line. The test device's control line is coated with secondary antibodies, which, under normal test procedure, a colored strip is drawn.
ESfEQA Evaluation Study: AESKU SARS-CoV-2 Antigen Rapid Test Performance
ESfEQA Evaluation Study: AESKU SARS-CoV-2 Antigen Rapid Test vs. Realtime PCR
Positive test results confirm the presence of viral antigens. Negative test results do not completely rule out COVID-19. However, a clinical history of the patient is still necessary to determine the infection status. The samples were tested in parallel with the RT-PCR test of a leading European manufacturer.
Lindner AK et al., Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-collected nasopharyngeal swab. Eur Respir J 2020. doi: 10.1183/13993003.03961-2020
Rozand, C. (2013). Paper-based analytical devices for point-of-care infectious disease testing. European Journal of Clinical Microbiology & Infectious Diseases, 33(2), 147–156. doi:10.1007/s10096-013-1945-2